Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination

BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV) is highly immunogenic and efficacious in adults ≥50 years of age. We evaluated (1) long-term immunogenicity of an initial 2-dose RZV schedule, by following up adults vaccinated at ≥60 years of age and by modeling, and (2) immunogenicity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hastie, Andrew, Catteau, Grégory, Enemuo, Adaora, Mrkvan, Tomas, Salaun, Bruno, Volpe, Stephanie, Smetana, Jan, Rombo, Lars, Schwarz, Tino, Pauksens, Karlis, Hervé, Caroline, Bastidas, Adriana, Schuind, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672743/
https://www.ncbi.nlm.nih.gov/pubmed/32502272
http://dx.doi.org/10.1093/infdis/jiaa300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672743/
https://www.ncbi.nlm.nih.gov/pubmed/32502272
http://dx.doi.org/10.1093/infdis/jiaa300

Ejemplares similares